Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 3, 2011, Pages 273-281

  Aboutabl, Mona E ^a   Zordoky, Beshay N M ^a   Hammock, Bruce D ^b   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

benzo(a)pyrene; cardiac hypertrophy; cytochrome P450; soluble epoxide hydrolase inhibitor; TUPS

Indexed keywords

1 (1 METHANESULFONYLPIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXYPHENYL)UREA; BENZO[A]PYRENE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 4F4; CYTOCHROME P450 4F5; EPOXIDE HYDROLASE; HEME OXYGENASE 1; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME INHIBITION; HEART; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ARACHIDONIC ACID; BENZO(A)PYRENE; BIOLOGICAL MARKERS; CARDIOMEGALY; CARDIOTONIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; GENE EXPRESSION PROFILING; HAZARDOUS SUBSTANCES; HEART; HEME OXYGENASE-1; KIDNEY; LIVER; MALE; MICROSOMES; PHENYLUREA COMPOUNDS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79952808052     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182055baf     Document Type: Article

References (43)

1. Korashy HM, El-Kadi AO. The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Rev. 2006;38:411-450.
2. Miller KP, Ramos KS. Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons. Drug Metab Rev. 2001;33:1-35. (Pubitemid 32193758)
3. Burstyn I, Kromhout H, Partanen T, et al. Polycyclic aromatic hydrocarbons and fatal ischemic heart disease. Epidemiology. 2005;16: 744-750. (Pubitemid 41681540)
4. Haritash AK, Kaushik CP. Biodegradation aspects of polycyclic aromatic hydrocarbons (PAHs): a review. JHazard Mater. 2009;169:1-15.
5. Ding YS, Trommel JS, Yan XJ, et al. Determination of 14 polycyclic aromatic hydrocarbons in mainstream smoke from domestic cigarettes. Environ Sci Technol. 2005;39:471-478. (Pubitemid 40129865)
6. Kanzawa N, Kondo M, Okushima T, et al. Biochemical and molecular biological analysis of different responses to 2,3,7,8-tetrachlorodibenzo-p- dioxin in chick embryo heart and liver. Arch Biochem Biophys. 2004; 427:58-67. (Pubitemid 38725914)
7. Aboutabl ME, Zordoky BN, El-Kadi AO. 3-Methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol. 2009;158:1808-1819.
8. Zordoky BN, El-Kadi AO. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol In Vitro. 2010;24: 863-871.
9. Borlak J, Thum T. PCBs alter gene expression of nuclear transcription factors and other heart-specific genes in cultures of primary cardiomyo-cytes: possible implications for cardiotoxicity. Xenobiotica. 2002;32: 1173-1183. (Pubitemid 36020943)
10. Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res. 2004;43:55-90. (Pubitemid 37433867)
11. Monti J, Fischer J, Paskas S, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 2008;40:529-537. (Pubitemid 351601216)
12. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci US A. 2009;106:564-569.
13. Xu D, Li N, He Y, et al. Prevention andreversal of cardiac hypertrophy by soluble epoxidehydrolase inhibitors. Proc Natl Acad Sci USA. 2006;103: 18733-18738. (Pubitemid 44913479)
14. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8:794-805.
15. Chabova VC, Kramer HJ, Vaneckova I, et al. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 2007;47:145-159. (Pubitemid 47096871)
16. Zordoky BN, Aboutabl ME, El-Kadi AO. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during iso-proterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos. 2008;36:2277-2286.
17. Tsai HJ, Hwang SH, Morisseau C, et al. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur JPharm Sci. 2010;40: 222-238.
18. Bleicher KB, Pippert TR, Glaab WE, et al. Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A. J Biochem Mol Toxicol. 2001;15:133-142. (Pubitemid 32514747)
19. Kalsotra A, Anakk S, Boehme CL, et al. Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab Dispos. 2002;30:1022-1028.
20. Hirasawa F, Kawagoe M, Arany S, et al. Styrene monomer primarily induces CYP2B1 mRNA in rat liver. Xenobiotica. 2005;35:1089-1099. (Pubitemid 43163248)
21. Rollin R, Mediero A, Fernandez-Cruz A, et al. Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol Vis. 2005;11:216-224. (Pubitemid 41358289)
22. Baldwin SJ, Bramhall JL, Ashby CA, et al. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase- polymerase chain reaction (TaqMan). Drug Metab Dispos. 2006;34:1063-1069. (Pubitemid 43763766)
23. Jin L, Foss CE, Zhao X, et al. Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J. 2006;20:539-541. (Pubitemid 46671242)
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression datausing real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408. (Pubitemid 34164012)
25. Barakat MM, El-Kadi AO, du Souich P. L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci. 2001;69: 1559-1571. (Pubitemid 32786729)
26. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
27. Gharavi N, El-Kadi AO. Tert-butylhydroquinone is a novel aryl hydrocarbon receptor ligand. Drug Metab Dispos. 2005;33:365-372. (Pubitemid 40279936)
28. Nithipatikom K, Grall AJ, Holmes BB, et al. Liquid chromatographic- electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem. 2001;298:327-336. (Pubitemid 33105250)
29. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol. 2005;45: 311-333. (Pubitemid 40261808)
30. Morisseau C, Goodrow MH, Dowdy D, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA. 1999; 96:8849-8854. (Pubitemid 29374671)
31. Chiamvimonvat N, Ho CM, Tsai HJ, et al. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol. 2007;50:225-237. (Pubitemid 47428969)
32. Lu T, Ye D, Wang X, et al. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol. 2006;575(pt 2):627-644. (Pubitemid 44270186)
33. Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway Circ Res. 2004;95: 506-514. (Pubitemid 39180931)
34. Batchu SN, Law E, Brocks DR, et al. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol. 2009;46:67-74.
35. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010;125:446-463.
36. Ishizuka T, Cheng J, Singh H, et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 2008;324:103-110. (Pubitemid 350294158)
37. Denison MS, Whitlock JP Jr. Xenobiotic-inducible transcription of cytochrome P450 genes. J Biol Chem. 1995;270:18175-18178.
38. Hu Y Ingelman-Sundberg M, Lindros KO. Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation. Biochem Pharmacol. 1995;50:155-161.
39. Kopf PG, Huwe JK, Walker MK. Hypertension, cardiac hypertrophy, and impaired vascular relaxation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are associated with increased superoxide. Cardiovasc Toxicol. 2008;8:181-193.
40. Reichard JF, Dalton TP, Shertzer HG, et al. Induction of oxidative stress responses by dioxin and other ligands of the aryl hydrocarbon receptor. Dose Response. 2005;3:306-331.
41. Peterson SJ, Frishman WH, Abraham NG Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev. 2009;17:99-111.
42. Iliff JJ, Alkayed NJ. Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent. Future Neurol. 2009;4:179-199.
43. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, et al. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol. 2010;242:38-46.